Showing results (21-30 of 103) with videos related to

Sort By:
Pageof 11
Chemotherapy|November 14, 2012
Pemetrexed for previously treated patients with non-small cell lung cancer and differences in efficacy according to thymidylate synthase expressionSatoshi Igawa, Shinichiro Ryuge, Mayuko Wada, et al.
Anticancer Research|February 6, 2009
Efficacy of amrubicin for non-small cell lung cancer after failure of two or more prior chemotherapy regimensSatoshi Igawa, Toshiaki Takahashi, Yukiko Nakamura, et al.
Oncology|May 29, 2016
Smoking History as a Predictor of Pemetrexed Monotherapy in Patients with Non-Squamous Non-Small Cell Lung CancerSatoshi Igawa, Jiichiro Sasaki, Sakiko Otani, et al.
Oncotargets and Therapy|November 16, 2017
S100A16, a promising candidate as a prognostic marker for platinum-based adjuvant chemotherapy in resected lung adenocarcinomaKen Katono, Yuichi Sato, Makoto Kobayashi, et al.
Nihon Kokyuki Gakkai Zasshi = the Journal of the Japanese Respiratory Society|May 2, 2003
[Case report of pulmonary epithelioid hemangioendothelioma]Nobuhide Hanada, Seiyu Namai, Chisato Kobayashi, et al.
Lung Cancer (Amsterdam, Netherlands)|August 28, 2016
Successful oral desensitization against skin rash induced by alectinib in a patient with anaplastic lymphoma kinase-positive lung adenocarcinoma: A case reportMasayuki Shirasawa, Masaru Kubotaa, Shinya Harada, et al.
Oncology|July 19, 2014
Comparison of the efficacy of gefitinib in patients with non-small cell lung cancer according to the type of epidermal growth factor receptor mutationSatoshi Igawa, Masashi Kasajima, Mikiko Ishihara, et al.
Biomedical Research (Tokyo, Japan)|June 12, 2020
Prognostic significance of NAP1L1 expression in patients with early lung adenocarcinomaRyo Nagashio, Yuki Kuchitsu, Satoshi Igawa, et al.
Biomedical Research (Tokyo, Japan)|February 22, 2019
Clinicopathological and prognostic significance of nuclear UGDH localization in lung adenocarcinomaDaisuke Hagiuda, Ryo Nagashio, Masaaki Ichinoe, et al.
Oncology Letters|April 30, 2017
Correlation between the efficacy of amrubicin and the previous chemotherapy regimen for relapsed small cell lung cancerMasashi Kasajima, Satoshi Igawa, Mikiko Ishihara, et al.
Pageof 11